10,000 Shares in uniQure (NASDAQ:QURE) Purchased by ADAR1 Capital Management LLC

ADAR1 Capital Management LLC acquired a new position in shares of uniQure (NASDAQ:QURE) in the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $177,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. lifted its position in shares of uniQure by 9.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 969 shares in the last quarter. Wells Fargo & Company MN grew its position in uniQure by 13.9% during the fourth quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock valued at $217,000 after purchasing an additional 1,503 shares in the last quarter. Twin Tree Management LP acquired a new position in uniQure in the 4th quarter valued at approximately $77,000. FNY Investment Advisers LLC purchased a new stake in uniQure in the 4th quarter worth approximately $88,000. Finally, Geode Capital Management LLC lifted its position in uniQure by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock worth $2,509,000 after buying an additional 6,362 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on QURE. Leerink Partners boosted their price target on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a report on Wednesday, December 11th. Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and boosted their target price for the company from $20.00 to $52.00 in a research note on Tuesday, December 10th. StockNews.com upgraded uniQure to a “sell” rating in a report on Tuesday, March 11th. Cantor Fitzgerald boosted their price target on uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research note on Tuesday, December 10th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $24.00 price objective on shares of uniQure in a research report on Tuesday, January 21st. One investment analyst has rated the stock with a sell rating, three have given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $38.80.

uniQure Price Performance

NASDAQ QURE opened at $8.76 on Tuesday. uniQure has a 1 year low of $3.73 and a 1 year high of $19.18. The company has a fifty day simple moving average of $13.11 and a 200 day simple moving average of $11.00. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The company has a market cap of $473.71 million, a P/E ratio of -1.77 and a beta of 0.42.

Insiders Place Their Bets

In other news, CEO Matthew C. Kapusta sold 6,717 shares of uniQure stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $11.32, for a total value of $76,036.44. Following the transaction, the chief executive officer now directly owns 580,795 shares in the company, valued at approximately $6,574,599.40. The trade was a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Christian Klemt sold 2,916 shares of the business’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $11.32, for a total value of $33,009.12. Following the transaction, the chief financial officer now directly owns 155,168 shares of the company’s stock, valued at $1,756,501.76. This represents a 1.84 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 90,830 shares of company stock valued at $961,401 in the last quarter. Insiders own 4.74% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.